BofA’s Hartnett says concentrated U.S. stock returns are likely to persist
LONDON - BSF Enterprise Plc (LSE: BSFA) (OTCQB: BSFAF), a company specializing in tissue-engineered materials, has announced the publication of its prospectus following the receipt of approval from the Financial Conduct Authority (FCA). This development comes in connection with the proposed issuance of up to 28,926,352 new ordinary shares, as previously discussed in announcements on December 4 and December 27, 2024.
The company successfully raised approximately £500,000 in December 2024 through the placement of 20,000,000 ordinary shares at 2.5 pence each, which were admitted to the FCA’s Official List and began trading on the London Stock Exchange (LON:LSEG)’s Main Market on December 27, 2024.
The current share issue primarily involves warrants from the December 2024 placement and the £2.9 million fundraising effort from March 2023. These warrants, if exercised, are priced at 5 pence and 34 pence per share, respectively.
At the annual general meeting on March 5, 2025, shareholders passed resolutions to approve the share allotment and the disapplication of pre-emption rights concerning the share issue. The prospectus is now publicly accessible on the company’s website and the National Storage Mechanism.
Applications will be submitted for the new ordinary shares, connected to the 2023 Fundraising Warrants and the 2024 Placing Warrants, to be admitted to the FCA’s Official List and to trading on the London Stock Exchange’s Main Market. Admission is expected to become effective within 10 business days of the warrant exercises, with trading commencing thereafter.
The new shares, once issued, will be fully paid and will rank equally with the existing ordinary shares of BSF Enterprise. They will also be free from any claims or encumbrances at the time of issuance. The company will make further announcements as necessary.
This information, based on a press release statement, is made available by RNS, the news service of the London Stock Exchange and is authorized by the Financial Conduct Authority in the United Kingdom (TADAWUL:4280). Terms and conditions may apply to the distribution of this information.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.